Compare Revvity Inc (RVTY) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while Vanguard S&P 500 Growth Index Fund ETF trades at $83.6. The key difference: Revvity Inc pays a 0.22% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none. Which is the better fit depends on your goals.
| RVTY | VOOG | |
|---|---|---|
Market Cap | $14.18B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $130.94 | $85.69 |
52-Week Low | $82.26 | $65.32 |
Enterprise Value | $16.50B | — |
Dividend Yield | 0.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
VOOG trades at $84.08, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on S&P 500 growth stocks, offering exposure to large-cap leaders with a low expense ratio of 0.07% (Vanguard, 2026). Recent news highlights strong long-term performance, including over 400% total returns in the past decade (The Motley Fool, 2026-09-07).
Outlook remains positive for growth-oriented investors, supported by institutional buying and media optimism. Key risks include tech sector concentration and market volatility. Analysts favor VOOG for its cost efficiency and historical outperformance, though valuation sensitivity persists amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
